Literature DB >> 21289630

MicroRNA-141 confers resistance to cisplatin-induced apoptosis by targeting YAP1 in human esophageal squamous cell carcinoma.

Yukako Imanaka1, Soken Tsuchiya, Fumiaki Sato, Yutaka Shimada, Kazuharu Shimizu, Gozoh Tsujimoto.   

Abstract

MicroRNAs (miRNAs) are endogenous non-coding RNAs that function as negative regulators of gene expression. Alterations in miRNA expression have been shown to affect tumor growth and response to chemotherapy. In this study, we explored the possible role of miRNAs in cisplatin resistance in esophageal squamous cell carcinoma (ESCC). First we assessed the sensitivity of nine human ESCC cell lines (KYSE series) to cisplatin using an in vitro cell viability assay, and then we compared the miRNA profiles of the cisplatin-sensitive and -resistant cell lines by miRNA microarray analysis. The two groups showed markedly different miRNA expression profiles, and 10 miRNAs were found to be regulated differentially between the two groups. When miR-141, which was the most highly expressed miRNA in the cisplatin-resistant cell lines, was expressed ectopically in the cisplatin-sensitive cell lines, cell viability after cisplatin treatment was increased significantly. Furthermore, we found that miR-141 directly targeted the 3'-untranslated region of YAP1, which is known to have a crucial role in apoptosis induced by DNA-damaging agents, and thus downregulated YAP1 expression. Our study highlights an important regulatory role for miR-141 in the development of cisplatin resistance in ESCC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21289630     DOI: 10.1038/jhg.2011.1

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  33 in total

Review 1.  The role of microRNA in esophageal squamous cell carcinoma.

Authors:  Kazuto Harada; Yoshifumi Baba; Takatsugu Ishimoto; Hironobu Shigaki; Keisuke Kosumi; Naoya Yoshida; Masayuki Watanabe; Hideo Baba
Journal:  J Gastroenterol       Date:  2016-01-21       Impact factor: 7.527

2.  MicroRNA-15b/16 Attenuates Vascular Neointima Formation by Promoting the Contractile Phenotype of Vascular Smooth Muscle Through Targeting YAP.

Authors:  Fei Xu; Abu Shufian Ishtiaq Ahmed; Xiuhua Kang; Guoqing Hu; Fang Liu; Wei Zhang; Jiliang Zhou
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-08-20       Impact factor: 8.311

Review 3.  Non-coding RNAs in pancreatic cancer: challenges and opportunities for clinical application.

Authors:  V Taucher; H Mangge; J Haybaeck
Journal:  Cell Oncol (Dordr)       Date:  2016-04-08       Impact factor: 6.730

Review 4.  The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment.

Authors:  Randy Johnson; Georg Halder
Journal:  Nat Rev Drug Discov       Date:  2013-12-13       Impact factor: 84.694

5.  MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines.

Authors:  Richard Hummel; Corina Sie; David I Watson; Tingting Wang; Alfiya Ansar; Michael Z Michael; Mark Van der Hoek; Joerg Haier; Damian J Hussey
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

Review 6.  Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes.

Authors:  Ding-Wu Shen; Lynn M Pouliot; Matthew D Hall; Michael M Gottesman
Journal:  Pharmacol Rev       Date:  2012-06-01       Impact factor: 25.468

Review 7.  MicroRNA as tools and therapeutics in lung cancer.

Authors:  Jennifer F Barger; S Patrick Nana-Sinkam
Journal:  Respir Med       Date:  2015-02-19       Impact factor: 3.415

8.  Proton pump inhibitors (PPIs) impact on tumour cell survival, metastatic potential and chemotherapy resistance, and affect expression of resistance-relevant miRNAs in esophageal cancer.

Authors:  Kirsten Lindner; Christiane Borchardt; Maren Schöpp; Anja Bürgers; Christian Stock; Damian J Hussey; Jörg Haier; Richard Hummel
Journal:  J Exp Clin Cancer Res       Date:  2014-09-01

9.  Circulating microRNAs in serum: novel biomarkers for patients with bladder cancer?

Authors:  Anna-Regina Scheffer; Stefan Holdenrieder; Glen Kristiansen; Alexander von Ruecker; Stefan C Müller; Jörg Ellinger
Journal:  World J Urol       Date:  2012-12-25       Impact factor: 4.226

10.  14-3-3σ confers cisplatin resistance in esophageal squamous cell carcinoma cells via regulating DNA repair molecules.

Authors:  Kenneth K Y Lai; Kin Tak Chan; Mei Yuk Choi; Hector K Wang; Eva Y M Fung; Ho Yu Lam; Winnie Tan; Lai Nar Tung; Daniel K H Tong; Raymond W Y Sun; Nikki P Lee; Simon Law
Journal:  Tumour Biol       Date:  2015-09-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.